Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression

Cancer

Volumn 107, Issue 11, 2006, Pages 2628-2636

  Osman, Iman ^a,c   Dai, Jie ^b   Mikhail, Maryann ^a   Navarro, Daniel ^b   Taneja, Samir S ^a   Lee, Peng ^a   Christos, Paul ^b   Shen, Ruoqian ^b   Nanus, David M ^b  

^a NEW YORK UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Akt; Neutral endopeptidase; Phosphatase and tensin homolog; Prostate cancer; Tumor suppressor protein

Indexed keywords

CELL SURFACE PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; PEPTIDASE; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; TETRACYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ANALYSIS; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; TUMOR MODEL; TUMOR XENOGRAFT;

ANIMALS; DISEASE PROGRESSION; ENZYME ACTIVATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; NEPRILYSIN; PHOSPHORYLATION; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; TRANSPLANTATION, HETEROLOGOUS;

EID: 33751560243     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22312     Document Type: Article

References (32)

1. Chu P, Arber DA. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol. 2000;113:374-382.
2. Albrecht M, Mittler A, Wilhelm B, et al. Expression and immunolocalisation of neutral endopeptidase in prostate cancer. Eur Urol. 2003;44:415-422.
3. Freedland SJ, Seligson DB, Liu AY, et al. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate. 2003;55:71-80.
4. Osman I, Yee H, Taneja SS, et al. Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res. 2004;10:4096-4100.
5. Liu AY, Roudier MP, True LD. Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol. 2004;165:1543-1556.
6. Papandreou CN, Usmani B, Geng YP, et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med. 1998;4:50-57.
7. Usmani BA, Shen R, Janeczko M, et al. Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clin Cancer Res. 2000;6:1664-1670.
8. Shen R, Sumitomo M, Dai J, et al. Identification and characterization of two androgen response regions in the human neutral endopeptidase gene. Mol Cell Endocrinol. 2000;170:131-142.
9. Sumitomo M, Milowsky M, Shen R, et al. Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res. 2001;61:3294-3298.
10. Sumitomo M, Iwase A, Zheng R, et al. Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell. 2004;5:67-78.
11. Sumitomo M, Shen R, Nanus DM. Involvement of neutral endopeptidase in neoplastic progression. Biochim Biophys Acta. 2005;1751:52-59.
12. Sumitomo M, Shen R, Goldberg JS, Dai J, Navarro D, Nanus DM. Neutral endopeptidase promotes phorbol ester-induced apoptosis in prostate cancer cells by inhibiting neuropeptide-induced protein kinase C delta degradation. Cancer Res. 2000;60:6590-6596.
13. Caruso RP, Levinson B, Melamed J, et al. Altered N-myc downstream-regulated gene 1 protein expression in African-American compared with Caucasian prostate cancer patients. Clin Cancer Res. 2004;10:222-227.
14. Shuch B, Mikhail M, Satagopan J, et al. Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol. 2004;22:4725-4729.
15. Mikhail M, Velazquez E, Shapiro R, et al. PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res. 2005;11:5153-5157.
16. Gimm O, Perren A, Weng LP, et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol. 2000;156:1693-1700.
17. Perren A, Weng LP, Boag AH, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol. 1999;155:1253-1260.
18. Trotman LC, Niki M, Dotan ZA, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003;1:E59.
19. Tawfic S, Niehans GA, Manivel JC. The pattern of CD10 expression in selected pathologic entities of the prostate gland. Hum Pathol. 2003;34:450-456.
20. Dai J, Shen R, Sumitomo M, et al. Tumor suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells. Clin Cancer Res. 2001;7:1370-1377.
21. Thomas GV, Horvath S, Smith BL, et al. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res. 2004;10:8351-8356.
22. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced state. Cancer Res. 1999;59:4921-4926.
23. Halvorsen OJ, Haukaas SA, Akslen LA. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res. 2003;9:1474-1479.
24. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004;22:2954-2963.
25. Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene. 2005;24:7465-7474.
26. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005;436:725-730.
27. Simpson L, Parsons R. PTEN: life as a tumor suppressor. Exp Cell Res. 2001;264:29-41.
28. Sumitomo M, Shen R, Walburg M, et al. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J Clin Invest. 2000;106:1399-1407.
29. Malik SN, Brattain M, Ghosh PM, et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res. 2002;8:1168-1171.
30. Ayala G, Thompson T, Yang G, et al. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res. 2004;10:6572-6578.
31. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17:1499-1507.
32. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines - part 1. J Urol. 2005;173:342-359.